KZR — Kezar Life Sciences Share News
0.000.00%
Last trade - 00:00Brief: Kezar Life Sciences Reports Second Quarter 2022 Financial Results And Provides Business Update
Kezar Life Sciences Inc reports results for the quarter ended in June - Earnings Summary
Kezar Life Sciences Inc expected to post a loss of 27 cents a share - Earnings Preview
Brief: Kezar Life Sciences Says Preliminarily Estimates That Cash, Equivalents And Marketable Securities As Of June 30, 2022 Were Approximately $307 Million
Kezar Life Sciences gains as kidney disorder drug shows promise in mid-stage study
Brief: Kezar Life Sciences Announces Positive Topline Results From The MISSION Phase 2 Trial Evaluating Zetomipzomib For The Treatment Of Patients With Lupus Nephritis
Kezar Life Sciences Inc reports results for the quarter ended in March - Earnings Summary
Brief: Kezar Life Sciences Reports Q1 2022 Results
Kezar Life Sciences Inc expected to post a loss of 28 cents a share - Earnings Preview
Kezar Life Sciences drops as lead drug efficacy data disappoints
Brief: Kezar Announces Topline Results From PRESIDIO Trial Of Zetomipzomib For The Treatment Of Dermatomyositis And Polymyositis
Kezar Life Sciences Inc reports results for the quarter ended in December - Earnings Summary
Brief: Kezar Reports Q4 And Year-End 2021 Financial Results
Kezar Life Sciences Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Kezar Life Sciences Says Preliminarily Estimates Its Cash, Cash Equivalents & Marketable Securities As Of Dec 31, 2021 Were About $208.4 Million
Brief: Kezar Life Sciences Inc - Entered Into A Sales Agreement With Respect To An At-The-Market Offering Program
Brokerages cheer Kezar after promising kidney disorder therapy data
U.S. STOCKS ON THE MOVE-Kezar Life Sciences, Traeger, Lucid
Brief: Kezar Life Sciences Announces Interim Results From Mission Phase 2 Trial In Patients With Lupus Nephritis